Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer.
- Author:
Qiong QIN
1
;
Jianming YING
;
Ning LYU
;
Lei GUO
;
Wenxue ZHI
;
Aiping ZHOU
2
;
Jinwan WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adaptor Proteins, Signal Transducing; metabolism; Adenocarcinoma; genetics; metabolism; mortality; pathology; Adenocarcinoma, Mucinous; genetics; metabolism; mortality; pathology; Adenosine Triphosphatases; metabolism; Age Factors; Analysis of Variance; Colonic Neoplasms; genetics; metabolism; mortality; pathology; DNA Mismatch Repair; DNA Repair Enzymes; metabolism; DNA-Binding Proteins; metabolism; Disease-Free Survival; Humans; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; metabolism; Neoplasm Recurrence, Local; Nuclear Proteins; metabolism; Prognosis; Retrospective Studies; Survival Rate
- From: Chinese Journal of Oncology 2015;37(8):591-596
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the relationship between DNA mismatch repair (MMR) and clinicopathologic features and prognosis in patients with stages II and III colon cancers.
METHODSThe clinical and pathological data of 440 patients with stage II/III colon cancer after radical resection were retrospectively reviewed and analyzed. Immunohistochemical staining was used to assess the expression of MMR proteins (MLH1, MSH2, MSH6 and PMS2), and the correlation between DNA MMR and clinicopathological features and prognosis of colon cancers was analyzed.
RESULTSOf the 440 tumor samples tested for DNA mismatch repair status, 90 (20.5%) demonstrated defective DNA mismatch repair and 350 (79.5%) had proficient DNA mismatch repair. Defective DNA mismatch repair (dMMR) was associated with young patients (≤ 60), proximal colon cancer, stage II, poorly differentiated adenocarcinoma and mucinous adenocarcinoma (P<0.05 for all). Among the 440 patients, 126 (28.6%) cases had recurrence or metastasis and 93 (21.1%) died during the median follow-up of 61.0 months. The five-year disease-free survival (DFS) rate was 82.2% among the patients with tumor exhibiting dMMR, significantly higher than that in patients with tumors exhibiting pMMR (68.9%, P=0.02). The univariate and mutlivariate analyses showed that the MMR status is an independent factor affecting 5-year disease-free survival and overall survival (OS) in colon cancer patients (P<0.05 for both).
CONCLUSIONSDefective DNA mismatch repair (dMMR) is associated with patients with proximal colon cancer, stage II and poorly defferentiated adenocarcinoma and mucinous adenocarcinoma. The prognosis for patients with dMMR is better than those with pMMR. dMMR may be a useful biomarker for the prognosis of colon cancer.
